Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SCLX 
Scilex Holding Company (SCLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SCLX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $490
1 Year Target Price $490
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.62% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 126.80M USD | Price to earnings Ratio - | 1Y Target Price 490 |
Price to earnings Ratio - | 1Y Target Price 490 | ||
Volume (30-day avg) 2 | Beta 1.33 | 52 Weeks Range 3.60 - 42.52 | Updated Date 08/29/2025 |
52 Weeks Range 3.60 - 42.52 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -15.54 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.12 | Actual -7.42 |
Profitability
Profit Margin -179.12% | Operating Margin (TTM) -206.27% |
Management Effectiveness
Return on Assets (TTM) -65.79% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 164469356 | Price to Sales(TTM) 2.87 |
Enterprise Value 164469356 | Price to Sales(TTM) 2.87 | ||
Enterprise Value to Revenue 3.72 | Enterprise Value to EBITDA -2.64 | Shares Outstanding 6955700 | Shares Floating 2918258 |
Shares Outstanding 6955700 | Shares Floating 2918258 | ||
Percent Insiders 21.43 | Percent Institutions 78.14 |
Upturn AI SWOT
Scilex Holding Company
Company Overview
History and Background
Scilex Holding Company is a biopharmaceutical company focused on developing, manufacturing and commercializing non-opioid therapies for patients suffering with pain. The company has evolved over time, focusing on acquiring and developing novel pain management solutions.
Core Business Areas
- Pain Management: Focuses on developing and commercializing non-opioid pain management products. Key product includes ZTlido, a lidocaine topical system.
- Pipeline Development: Research and development efforts targeted at creating innovative therapies for various types of pain, including neuropathic pain.
Leadership and Structure
Dr. Henry Ji serves as the Chairman of the Board, and Jaisim Shah is the Chief Executive Officer. The company operates with a management team focused on commercializing existing products and advancing their pipeline.
Top Products and Market Share
Key Offerings
- ZTlido: ZTlido is a lidocaine topical system indicated for the relief of pain associated with post-herpetic neuralgia. Market share data is not readily available, but it competes with other topical analgesics and generics. Competitors: Lidoderm (Endo International), generic lidocaine patches.
Market Dynamics
Industry Overview
The pain management market is a large and growing market, driven by aging populations and increasing prevalence of chronic pain conditions. The demand for non-opioid alternatives is increasing due to concerns about opioid addiction.
Positioning
Scilex is positioned as a company focused on non-opioid pain management solutions, aiming to capitalize on the growing demand for safer alternatives to opioids. Their competitive advantage lies in their focus and expertise in this specific area.
Total Addressable Market (TAM)
The global pain management market is estimated to be worth hundreds of billions of dollars. Scilex is positioned to capture a portion of this market with its non-opioid products, focusing primarily on neuropathic pain.
Upturn SWOT Analysis
Strengths
- Focus on non-opioid pain management
- ZTlido commercialization
- Experienced management team
- Innovative pipeline
Weaknesses
- Limited product portfolio
- High reliance on ZTlido
- Relatively small market capitalization
- Dependence of the success of Scilex on a Bankruptcy process by its parent company.
Opportunities
- Expansion of non-opioid product offerings
- Partnerships and acquisitions
- Market growth in pain management
- Increasing demand for non-opioid alternatives
Threats
- Competition from larger pharmaceutical companies
- Generic competition
- Regulatory changes
- Patent expirations
Competitors and Market Share
Key Competitors
- Endo International (ENDP)
- Pacira BioSciences (PCRX)
- Assertio Holdings (ASRT)
Competitive Landscape
Scilex faces stiff competition from larger pharmaceutical companies with established pain management products. Scilex's advantage lies in its focus on non-opioid alternatives, but it needs to build market share and expand its product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires financial data not available in this text based model.
Future Projections: Future projections require financial data and analyst estimates not available in this text based model.
Recent Initiatives: Focusing on expanding the market reach of ZTlido and developing their pipeline of non-opioid pain therapies. Also, Scilex needs to survive the process of the parent company bankruptcy.
Summary
Scilex Holding Company is a biopharmaceutical company with a specific focus on non-opioid pain management. ZTlido is their primary revenue source. The company faces competition from larger players and needs to expand its portfolio and survive the parent company bankruptcy. The future success of Scilex Holding Company depends on its ability to successfully commercialize existing products and develop new non-opioid therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports (where available)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scilex Holding Company
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2021-03-05 | CEO, President & Executive Chairman Dr. Henry H. Ji Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 31 | Website https://www.scilexholding.com |
Full time employees 31 | Website https://www.scilexholding.com | ||
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.